SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information <u>(including phone and fax #s)</u> on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

NON-PREFERRED

*Member must have tried and failed preferred

□ HP Acthar[®] Gel (repository corticotropin)

Drug Requested: Repository Corticotropin Medications - Symptomatic Sarcoidosis

PREFERRED

□ Purified Cortrophin[™] Gel

(repository corticotropin)

prolonged therapy.

	Purified Cortrophin [™] Gel and meet all applicable			
	PA criteria below			
MEMBER & PRESCRIBER INFORM	MATION: Authorization may be delayed if incomplete.			
Member Name:				
Member Sentara #:	Date of Birth:			
Prescriber Name:				
Prescriber Signature:				
Office Contact Name:				
Phone Number:	Fax Number:			
DEA OR NPI #:				
DRUG INFORMATION: Authorization	may be delayed if incomplete.			
Drug Form/Strength:				
Dosing Schedule:	Length of Therapy:			
Diagnosis:	ICD Code, if applicable:			
Weight:	Date:			

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Adverse effects that may occur with repository corticotropin are related primarily to its <u>steroidogenic effects and</u> <u>are similar to corticosteroids</u>. There may be increased susceptibility to new infection and increased risk of reactivation of latent infections. Adrenal insufficiency may occur after abrupt withdrawal of the drug following

PA Repository Corticotropin_Sarcoidosis (Medicaid) (Continued from previous page)

	Member MUST have a documented di	•		_		
	☐ With active pulmonary symptoms	OR 🗆	Extra puli	monary symptoms only		
	AND					
	Member must have tried and failed or has a contraindication to systemic corticosteroids as follows: □ Trial of dose equivalent to at least 20 mg prednisone daily for 3 months Must be noted in pharmacy claims					
	OR					
	☐ For contraindication: GI BLEED has occurred within the last 30 days (must submit chart note documentation)					
	AND					
	Member must have tried and failed or has a contraindication to at least one (1) of the following immunomodulators (therapy tried must be noted in pharmacy claims):					
	□ methotrexate	□ azathioprine				
	AND					
	Member must have tried and failed or has a contraindication to at least one (1) TNF Inhibitor (therapy tried must be noted in pharmacy claims):					
	□ infliximab	□ etanercept (Er	ibrel®)	□ adalimumab (Humira®)		
	AND					
	Documentation that <u>EITHER</u> pulmonary imaging/pulmonary function tests <u>OR</u> noncaseating granulon showed worsening of disease while on a steroid and immunomodulator and TNF-Inhibitor (progress no and diagnostics <u>MUST</u> be submitted):					
	☐ Pulmonary imaging	OR 🗆	Confirma	tion of noncaseating granulomas		
	☐ Recent pulmonary function tests					
Medication being provided by a Specialty Pharmacy- PropriumRx						

** <u>Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.</u> **

*<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u> *